Compagnie Lombard Odier SCmA’s Adaptimmune Therapeutics ADAP Stock Holding History

Compagnie Lombard Odier SCmA’s Portfolio ADAP Stock Details ADAP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-57,560	Closed	-$471K	–	639
2017 Q3	$471K	Hold	57,560	–	–	0.02%	274
2017 Q2	$258K	Hold	57,560	–	–	0.01%	330
2017 Q1	$317K	Hold	57,560	–	–	0.01%	323
2016 Q4	$233K	Hold	57,560	–	–	0.01%	426
2016 Q3	$406K	Hold	57,560	–	–	0.01%	379
2016 Q2	$469K	Hold	57,560	–	–	0.01%	347
2016 Q1	$468K	Buy	57,560 +50,000	+661%	+$409K	0.01%	348
2015 Q4	$91K	Buy	+7,560	New	+$74K	﹤0.01%	609

Other funds holding ADAP

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

OIM

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Compagnie Lombard Odier SCmA's ADAP Position: Q4 2017 in Review

Compagnie Lombard Odier SCmA sold out of Adaptimmune Therapeutics (ADAP) in Q4 2017, closing a stake of 57,560 shares — an estimated $471K sold.

Compagnie Lombard Odier SCmA first reported a position in ADAP in Q4 2015 and held it in 8 quarters. The position peaked at $471K in Q3 2017. 71 funds tracked by Wall St. Rank hold ADAP as of Q4 2017.

Compagnie Lombard Odier SCmA reported no remaining Adaptimmune Therapeutics position as of Q4 2017 after selling out during the quarter.
Compagnie Lombard Odier SCmA sold 57,560 Adaptimmune Therapeutics shares in Q4 2017, an estimated $471K.
Compagnie Lombard Odier SCmA first reported a position in Adaptimmune Therapeutics in Q4 2015 and held it in 8 quarters.
Compagnie Lombard Odier SCmA's Adaptimmune Therapeutics position peaked at $471K in Q3 2017.
71 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q4 2017.

Based on Compagnie Lombard Odier SCmA's 13F filing for Q4 2017, filed 13 Feb 2018.